HEOR

News

NICE backs NHS use of Autolus' leukaemia CAR-T

Hundreds of people with an aggressive leukaemia will be able to access a CAR-T therapy developed by UK biotech Autolus after a NICE recommendation.

News

Alnylam's ATTR cardiomyopathy drug backed for NHS use

Patients with ATTR-CM in England and Wales will soon have a new treatment option, after NICE backed use of Alnylam's three-month injectable Amvuttra.

News

NICE backs five AI tools for bowel cancer screening

Five AI technologies used during a colonoscopy exam to help detect the early signs of bowel cancer have been backed for use by the NHS in England.

News

NICE backs Roche's non-Hodgkin lymphoma drug Columvi

NICE backs NHS use of Roche's Columvi as a second-line therapy for a form of non-Hodgkin lymphoma affecting thousands of people in the UK each year.

News

"Significant shift" as NICE widens prostate cancer drug use

NICE has changed unpopular guidance on abiraterone for hormone-sensitive prostate cancer after the entry of generics into the UK market.

News

A male HCP discusses treatment with an older male patient

Bayer's prostate cancer drug Nubeqa cleared for NHS use

Thousands of men living with incurable prostate cancer will be able to access an easier-to-tolerate treatment from Bayer, thanks to new NICE guidance.

NICE backs NHS use of Autolus' leukaemia CAR-T

Alnylam's ATTR cardiomyopathy drug backed for NHS use

NICE backs five AI tools for bowel cancer screening

NICE backs Roche's non-Hodgkin lymphoma drug Columvi

"Significant shift" as NICE widens prostate cancer drug use

Bayer's prostate cancer drug Nubeqa cleared for NHS use

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

HEOR

Editor's Picks